Horizon Technology Finance(US:HRZN)2026-03-04 15:02Financial Data and Key Metrics Changes - The company generated net investment income (NII) of $0.18 per share for Q4 2025, down from $0.32 per share in Q3 2025 and $0.27 per share in Q4 2024 [23] - The net asset value (NAV) per share was $6.98 as of December 31, 2025, compared to $7.12 as of September 30, 2025, and $8.43 as of December 31, 2024 [26] - Total investment income for Q4 2025 was $21 million, down from $24 million in the prior year period, primarily due to lower interest income on the debt investment portfolio [22] Business Line Data and Key Metrics Changes - The company achieved a portfolio yield on debt investments of over 14% for Q4 2025 and nearly 16% for the full year 2025, maintaining a position at or near the top of the BDC industry [8] - The debt investment portfolio on a net cost basis stood at $602 million as of December 31, 2025, up 3% from $585 million as of September 30, 2025 [22] - New originations totaled $103 million in Q4 2025, offset by $13 million in scheduled principal payments and $15 million in principal prepayments, refinancings, and partial pay downs [25] Market Data and Key Metrics Changes - Approximately $92 billion was invested in VC-backed companies in Q4 2025, with 2025 being the largest year of investment since 2021 at $339 billion [15] - The demand for venture debt capital remains high, and the company expects to be a key supplier of such capital in the coming year and beyond [9] Company Strategy and Development Direction - The company is preparing for a merger with Monroe Capital, which is expected to significantly increase equity capital available for investment and allow for larger venture loans [5][10] - The merger is anticipated to enhance the company's ability to target larger venture loan opportunities for both private and small-cap public companies [18] - The company aims to optimize outcomes with respect to its current portfolio while expanding its venture lending capabilities [19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that 2025 was a year of transformation, navigating various challenges while laying groundwork for long-term success [4] - The company remains optimistic about the venture lending market, particularly in AI and defense technology sectors, and believes venture debt is a compelling option for companies seeking capital with lower dilution [17] - Management expects to generate NII that covers distributions over time, supported by a strong pipeline of investment opportunities [24] Other Important Information - The company ended the year with a committed and approved backlog of $154 million, up from $119 million at the end of Q3 2025 [13] - The company redeemed its notes due in 2026 with proceeds from the issuance of 7% notes due 2028 [8] Q&A Session Summary Question: Inquiry about the new dividend level decision - Management reviews distribution levels with the board each quarter, considering the current portfolio, run rate, spillover, and growth opportunities to determine a sustainable level [29] Question: Clarification on the percentage at contractual floor - The percentage at contractual floor is 71% [30] Question: Understanding the earnings slide quarter-over-quarter - The lower interest income was primarily driven by lower prepayment activity and the timing of fundings, with significant prepayments occurring in Q3 [35] Question: Opportunities for public company financing - The company offers flexible capital structures that are less dilutive compared to equity, targeting companies that may not be profitable enough to access traditional bank financing [39] Question: Status of non-accrual portfolio companies - The company is working to maximize recoveries from non-accruals, which are at various levels, and has improved the percentage of non-accruals quarter-over-quarter [43] Question: Drivers of realized loss from Tallac Therapeutics - Tallac was a small part of the realized loss, with the overall realized loss being slightly positive for the quarter [48]